Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-23-256183
Filing Date
2023-10-13
Accepted
2023-10-13 17:28:49
Documents
1
Group Members
ATHYRIUM FUNDS GP HOLDINGS LLCATHYRIUM OPPORTUNITIES ASSOCIATES IV CO-INVEST LLCATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLCATHYRIUM OPPORTUNITIES ASSOCIATES IV LPATHYRIUM OPPORTUNITIES IV CO-INVEST 2 LPJEFFREY A. FERRELL

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d563476dsc13da.htm SC 13D/A 127649
  Complete submission text file 0001193125-23-256183.txt   129675
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Subject) CIK: 0001739426 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90830 | Film No.: 231325778
SIC: 2834 Pharmaceutical Preparations

Mailing Address 505 FIFTH AVENUE FLOOR 18 NEW YORK NY 10017
Business Address 505 FIFTH AVENUE FLOOR 18 NEW YORK NY 10017 212-402-6925
Athyrium Opportunities IV Acquisition 2 LP (Filed by) CIK: 0001888848 (see all company filings)

EIN.: 872028841 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A